Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 274 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sclerosis, Systemic Clear all
Completed Not applicable Interventional

Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc)

NCT07402863
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
RENEW
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

NCT01309997
View directory record Official record
Conditions
Graft Versus Host Disease, Systemic Scleroderma
Interventions
imatinib mesylate, rituximab
Drug · Biological
Lead sponsor
Lee, Stephanie
Other
Eligibility
2 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Oct 29, 2026, 10:47 PM EDT
Terminated Phase 1 Interventional

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

NCT00418132
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Thalidomide, Placebo thalidomide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Riociguat in Scleroderma Associated Digital Ulcers

NCT02915835
View directory record Official record
Conditions
Scleroderma, Digital Ulcers
Interventions
Riociguat, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

NCT00613171
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
STI571
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 29, 2026, 10:47 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Tibial Delayed Healing Pivotal Clinical Trial

NCT01016067
View directory record Official record
Conditions
Tibial Delayed Healing
Interventions
INFUSE/MASTERGRAFT, Autograft bone
Device · Procedure
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
21 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
16
States / cities
Denver, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 29, 2026, 10:47 PM EDT
Not yet recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
17
States / cities
Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis

NCT06827977
View directory record Official record
Conditions
Constipation, Bloating
Interventions
PRIM-DJ2727, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Phase 2 Interventional

Proof of Biological Activity of SAR100842 in Systemic Sclerosis

NCT01651143
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
SAR100842, Placebo (for SAR100842)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

NCT01393132
View directory record Official record
Conditions
Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye drops, Vehicle Control
Drug
Lead sponsor
Michigan Cornea Consultants, PC
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin in the Treatment of Raynaud's

NCT01233999
View directory record Official record
Conditions
Raynaud's Syndrome
Interventions
botulinum toxin A
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Not applicable Interventional

Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention

NCT04588714
View directory record Official record
Conditions
Scleroderma
Interventions
Resilience-based, Energy Management to Enhance Wellbeing (RENEW)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 29, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional

Systemic Sclerosis DIet for GastrointESTinal Symptoms

NCT07402226
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Diet 1: Restriction of fermentable carbohydrates, Diet 2: Elimination of foods harmful to gut barrier and microbiome, Diet 3: Regular meal patterns, soluble fiber, and portion control
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978
View directory record Official record
Conditions
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Interventions
FT819, Fludarabine, Cyclophosphamide, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
16
States / cities
Beverly Hills, California • Fullerton, California • Irvine, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114
View directory record Official record
Conditions
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Interventions
Allogeneic NK Cells
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
31
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

NCT00025818
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 29, 2026, 10:47 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07085104
View directory record Official record
Conditions
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions
ALLO-329, Cyclophosphamide, Fludarabine
Genetic · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
16
States / cities
Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

NCT04166552
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Patients will be randomized to receive EHP-101 or Placebo
Drug
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin for Systemic Sclerosis

NCT03222492
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions
Brentuximab Vedotin, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

NCT07403188
View directory record Official record
Conditions
Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
Interventions
KYV-101
Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Recruiting Phase 1 Interventional

A Study of AZD0120 in Autoimmune Diseases

NCT07295847
View directory record Official record
Conditions
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions
AZD0120
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Tucson, Arizona • Stanford, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 29, 2026, 10:47 PM EDT
Completed Not applicable Interventional

Online Fatigue Intervention Program for People With Scleroderma

NCT04401943
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
online fatigue intervention
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 29, 2026, 10:47 PM EDT
Terminated Phase 2 Interventional Results available

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

NCT03976648
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
GLPG1690
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Boca Raton, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 29, 2026, 10:47 PM EDT